Sarepta Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRPT research report →
Companywww.sarepta.com
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
- CEO
- Douglas S. Ingram
- IPO
- 1997
- Employees
- 1,372
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.81B
- P/E
- 27.63
- P/S
- 0.83
- P/B
- 1.19
- EV/EBITDA
- 19.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 62.39%
- Op Margin
- -1.88%
- Net Margin
- 2.98%
- ROE
- 4.89%
- ROIC
- -1.53%
Growth & Income
- Revenue
- $2.20B · 15.58%
- Net Income
- $-713,410,000 · -403.27%
- EPS
- $-7.13 · -388.66%
- Op Income
- $-657,772,000
- FCF YoY
- 12.84%
Performance & Tape
- 52W High
- $44.14
- 52W Low
- $10.42
- 50D MA
- $20.08
- 200D MA
- $19.98
- Beta
- 0.26
- Avg Volume
- 3.06M
Get TickerSpark's AI analysis on SRPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 26 | Estepan Ian Michael | other | 1,097 |
| Mar 11, 26 | Wong Ryan Ho-Yan | other | 256 |
| Mar 11, 26 | Rodino-Klapac Louise | other | 948 |
| Mar 12, 26 | Mayo Stephen | sell | 7,239 |
| Mar 11, 26 | Rothfuss Cristin | other | 974 |
| Mar 9, 26 | Wong Ryan Ho-Yan | other | 162 |
| Mar 9, 26 | Wong Ryan Ho-Yan | other | 113 |
| Mar 9, 26 | Rothfuss Cristin | other | 484 |
| Mar 9, 26 | Rothfuss Cristin | other | 346 |
| Mar 9, 26 | Rodino-Klapac Louise | other | 504 |
Our SRPT Coverage
We haven't published any research on SRPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SRPT Report →